Hypertriglyceridemia
Therapeutic area
Metabolic Disease
Rare disease
No
- Definition
- A laboratory test result indicating elevated triglyceride concentration in the blood.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Hypertriglyceridemia
- Therapeutic area
- Metabolic Disease
- hypertriglyceridemia
- hypertriglyceridemia
- hypertriglyceridemia (disease)
- All therapeutic areas
- Metabolic Disease
- Severity
- Mild
- MONDO ID
- MONDO:0005347
- Parent condition
- MONDO:0005066
Related records
Broader conditions (4)
- Disease
- Disease by developmental or physiological process
- Human disease
- Metabolic disease
Narrower conditions (2)
- Hypertriglyceridemia 1
- Hypertriglyceridemia 2
Trials (1,405)
- (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
- A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
- A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)
- A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
- A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
- A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
- A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
- A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
- A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)
- A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink
- A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
- A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
- A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
- A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
- A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia
- A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
- A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Approved drugs (1)
- Icosapent ethyl
Drugs in development (38)
- Aspirin Phase 1
- Atorvastatin Phase 3
- Ciprofloxacin Phase 3
- CORN OIL Phase 3
- Diazoxide choline Phase 2
- Epeleuton Phase 2
- Evinacumab Phase 2
- Ezetimibe Phase 3
- Fenofibrate Phase 3
- Fenofibric acid Phase 3
- Gemcabene Phase 2
- Gemfibrozil Phase 1
- GS-9667 Phase 1
- Icosapent Phase 3
- Implitapide Phase 2
- K-877 Phase 3
- Maraviroc Phase 1
- Olezarsen Phase 3
- Olezarsen sodium Phase 1
- Olive oil Phase 3
Other linked drugs (2)
- Bezafibrate
- Doconexent